Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P41597: Variant p.Thr296Asn

C-C chemokine receptor type 2
Gene: CCR2
Feedback?
Variant information Variant position: help 296 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Threonine (T) to Asparagine (N) at position 296 (T296N, p.Thr296Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and polar. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In PCLUD; likely pathogenic; loss of CCL2 or CCL13 cytokine-mediated signaling pathway; loss of expression at the cell surface; contrary to wild-type, does not rescue CCL2 cytokine-mediated calcium mobilization and cell migration, when transfected in CCR2-null monocytic THP-1 cells. Any additional useful information about the variant.


Sequence information Variant position: help 296 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 374 The length of the canonical sequence.
Location on the sequence: help NCESTSQLDQATQVTETLGM T HCCINPIIYAFVGEKFRSLF The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         NCESTSQLDQATQVTETLGMTHCCINPIIYAFVGEKFRSLF

Rhesus macaque                NCESTRQLDQATQVTETLGMTHCCINPIIYAFVGEKFRRYL

Mouse                         NCVIDKHLDQAMQVTETLGMTHCCINPVIYAFVGEKFRRYL

Rat                           NCVVDMHLDQAMQVTETLGMTHCCVNPIIYAFVGEKFRRYL
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 374 C-C chemokine receptor type 2
Transmembrane 286 – 309 Helical; Name=7
Turn 296 – 300



Literature citations
Human inherited CCR2 deficiency underlies progressive polycystic lung disease.
Neehus A.L.; Carey B.; Landekic M.; Panikulam P.; Deutsch G.; Ogishi M.; Arango-Franco C.A.; Philippot Q.; Modaresi M.; Mohammadzadeh I.; Corcini Berndt M.; Rinchai D.; Le Voyer T.; Rosain J.; Momenilandi M.; Martin-Fernandez M.; Khan T.; Bohlen J.; Han J.E.; Deslys A.; Bernard M.; Gajardo-Carrasco T.; Soudee C.; Le Floc'h C.; Migaud M.; Seeleuthner Y.; Jang M.S.; Nikolouli E.; Seyedpour S.; Begueret H.; Emile J.F.; Le Guen P.; Tavazzi G.; Colombo C.N.J.; Marzani F.C.; Angelini M.; Trespidi F.; Ghirardello S.; Alipour N.; Molitor A.; Carapito R.; Mazloomrezaei M.; Rokni-Zadeh H.; Changi-Ashtiani M.; Brouzes C.; Vargas P.; Borghesi A.; Lachmann N.; Bahram S.; Crestani B.; Pahari S.; Schlesinger L.S.; Marr N.; Bugonovic D.; Boisson-Dupuis S.; Beziat V.; Abel L.; Borie R.; Young L.R.; Deterding R.; Shahrooei M.; Rezaei N.; Parvaneh N.; Craven D.; Gros P.; Malo D.; Sepulveda F.E.; Nogee L.M.; Aladjidi N.; Trapnell B.C.; Casanova J.L.; Bustamante J.;
Cell 187:390-408(2024)
Cited for: INVOLVEMENT IN PCLUD; VARIANTS PCLUD ARG-61; ARG-119; 214-PRO-LEU-215 DEL AND ASN-296; FUNCTION; SUBCELLULAR LOCATION; TISSUE SPECIFICITY; CHARACTERIZATION OF VARIANTS PCLUD ARG-61; ARG-119; 214-PRO-LEU-215 DEL AND ASN-296; VARIANTS ILE-64; PHE-133; LEU-316 AND ASP-355; CHARACTERIZATION OF VARIANTS ILE-64; PHE-133; LEU-316 AND ASP-355;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.